Convergent Therapeutics, Inc.
Scott Myers is an accomplished executive in the biopharmaceutical industry, currently serving as the Chairman of the Board at Convergent Therapeutics, Inc., and Dynavax Technologies Corporation, a company specializing in novel vaccines. With a background that includes leadership roles at Ironshore Therapeutics, Harpoon Therapeutics, and Viridian Therapeutics, Scott has extensive experience in guiding organizations through significant transitions, including acquisitions by major pharmaceutical companies like Merck and Pfizer. Scott's expertise also extends to independent directorships and advisory positions, notably at Selecta Biosciences and Qiming Venture Partners USA. Academic credentials include an MBA in Finance and International Business from The University of Chicago Booth School of Business and a Bachelor of Arts in Biology from Northwestern University.
This person is not in any teams
Convergent Therapeutics, Inc.
Convergent Therapeutics is a clinical-stage biotechnology company exploring the full potential of dual-targeted combination strategies to treat cancer. Convergent has developed a therapeutic platform that is capable of targeting validated and novel cancer antigens. Building on breakthrough research developed by Dr. Neil Bander at Weill Cornell Medicine, Convergent has demonstrated that dual targeting of surface cancer molecules like Prostate-Specific Membrane Antigen (PSMA) improves antitumor efficacy. By leveraging targeting agents with different bio-distributions, such as monoclonal antibodies and ligands, supra-additive therapeutic doses are delivered to tumor cells without additive toxicity to the patient.